Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.39 |
| ▸ | LMNA | P02545 | 6/20 | 0.39 |
| ▸ | RAB9A | P51151 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | MITF | O75030 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 9/20 | 0.37 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2734801 | 0.87 | NR4A2 (0.40) | NR4A2KMT2ALMNARAB9AALDH1A1 | |
| SCHEMBL3624515 | 0.76 | NR4A2 (0.65) | NR4A2KMT2ALMNARAB9AALDH1A1 | |
| SCHEMBL3483291 | 0.73 | NR4A2 (0.41) | NR4A2KMT2ALMNARAB9AALDH1A1 | |
| SCHEMBL4847195 | 0.73 | AHR (0.52) | RAB9AALDH1A1MAPTNPC1HSD17B10 | |
| SCHEMBL5676154 | 0.72 | ITGB3 (0.32) | — | |
| SCHEMBL693676 | 0.72 | AHR (0.32) | — | |
| SCHEMBL5670227 | 0.68 | MAP2 (0.40) | KMT2ARAB9AALDH1A1MAPTNPC1 | |
| SCHEMBL3628074 | 0.68 | MAP2 (0.50) | LMNAMAPTGAASMN1; SMN2PTGS1 | |
| SCHEMBL166213 | 0.68 | ALDH1A1 (0.39) | ALDH1A1HSD17B10 | |
| SCHEMBL2466230 | 0.67 | JAK2 (0.42) | RAB9AALDH1A1NPC1SMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | BIOTIE THERAPIES CORPORATION (FI) | 2008-10-16 | — | — | US | disclosed |
| EP-1732884-A1 | SULPHONAMIDE DERIVATIVES | Biotie Therapies Corp. (FI) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005090298-A1 | SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | NR1I2, ITGA2, ITGB2 | NR4A2 82/4885KMT2A 1119/4885LMNA 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.